摘要
目的探讨晚期非小细胞肺癌患者经润肺散结汤辅助埃克替尼治疗前后血清Lemur酪氨酸激酶3(LMTK-3)及POK红系髓性致癌因子(Pokemon)变化情况分析。方法选取2017年3月至2018年3月我院就诊的88例晚期非小细胞肺癌患者,分为观察组和对照组各44例。对照组患者给予埃克替尼进行治疗,观察组患者在对照组的基础上给予润肺散结汤进行治疗,比较2组患者治疗后临床疗效和治疗前后肿瘤标志物水平、血清LMTK-3、血清Pok-mon水平表达生活质量及治疗期间不良反应,并随访2年2组患者远期生存情况。结果治疗后,观察组总缓解率48%和总控制率89%显著高于对照组的25%和70%(P<0.05)。治疗后,2组患者血清糖类抗原(CA)199、CA125、癌胚抗原(CEA)、鳞状细胞癌抗原(SCC)等血清标志物水平较治疗前显著降低,且观察组低于对照组(P<0.05)。治疗后2组患者血清LMTK-3表达水平较治疗前显著降低,且观察组血清LMTK-3(8.3±2.3)ng/ml显著低于对照组的(10.4±2.5)ng/m(P<0.05)。治疗后2组患者血清Pokemon表达水平较治疗前显著降低,且观察组血清Pokemon(45±6)ng/ml显著低于对照组的(74±6)ng/ml(P<0.05)。治疗后2组患者体能、精神影响、社会活动、心理健康、体能影响、精力、身体疼痛和一般健康等各项评分较显著优于治疗前,且观察组各项评分优于对照组(P<0.05)。治疗期间,2组患者出现Ⅲ~Ⅳ级腹泻和转氨酶升高情况相当(P>0.05),但观察组出现Ⅲ~Ⅳ级皮疹的发生率显著低于对照组(P<0.05)。随访治疗后6个月和9个月结果发现,2组患者无进展生存期相当(P>0.05),而12个月、18个月和24个月时观察组患者的无进展生存期优于对照组(P<0.05)。结论润肺散结汤辅助埃克替尼可较好控制和缓解晚期非小细胞肺癌患者肿瘤情况,降低其肿瘤标注物水平表达,提高患者生活质量和远期生存时间,安全性较好,为晚期非小细胞肺癌患者的治疗提供了可靠指导。
Objective To investigate the changes in serum LMTK-3 and pokemon levels before and after treatment with Runfei Sanjie Decoction in patients with advanced non-small cell lung cancer.Methods A total of 88 patients with advanced non-small cell lung cancer in our hospital between March 2017 and March 2018 were included and divided into the study group and control group(n=44 each).The patients in the control group were treated with icotinib;in addition to this,the patients in the study group were given Runfei Sanjie decoction.The clinical efficacy,serum presentation levels of tumor markers.LMTK-3 and Pokmon quality of life and adverse reactions during treatment were compared between the two groups of patients at baseline and after treatment.The patients were followed up for 2 years and recorded for long-term survival.Results After treatment,the overall remission rate and total control rate in the study group(48%and 89%)were significantly higher than those in the control group(25%and 70%)(P<0.05).After treatment,the serum levels of tumor biomarkers CA199,CA125,CEA,and SCC were significantly lower than baseline in either group,and were lower in the study group than those in the control group(P<0.05).After treatment,the serum LMTK-3 expression level was significantly lower than baseline in either group,and was significantly lower in the study group than that in the control group[(8.3±2.3)ng/ml vs(10.4±2.5)ng/m,P<0.05].After treatment,the serum Pokemon expression level was significantly lower than baseline,and was significantly lower in the study group than that in the control group[(45±6)ng/ml vs(74±6)ng/ml,P<0.05].After treatment,the scores of physical functioning,role emotional,social functioning,mental health,role physical,vitality,bodily pain and general health were significantly improved in either group compared with baseline,and these scores were more improved in the study group compared with the control group(P<0.05).During the treatment,the two groups of patients experienced gradeⅢ-Ⅳdiarrhea and elevated transaminase(P>0.05),but the incidence of gradeⅢ-Ⅳrash was significantly lower in the study group than that in the control group(P<0.05).At six and nine months of follow-up,the two groups showed comparable progression-free survival(P>0.05);however,at 12,18,and 24 months of follow-up,the study group showed more favorable progression-free survival compared with the control group(P<0.05).Conclusion In patients with advanced non-small cell lung cancer,Runfei Sanjie decoction added to icotinib therapy can result in better oncological control and remission,lowered level of tumor biomarkers,improved quality of life and long-term survival,as well as good safety.This offers reliable evidence for the treatment of advanced non-small cell lung cancer.
作者
孟田田
张桐桐
邓秋
赵跃萍
Meng Tiantian;Zhang Tongtong;Deng Qiu;Zhao Yueping(Department of Critical care Rehabilitation Unit,Affiliated Hospital of Liaoning University of Traditional Chinese Medicine,Shenyang 110032,China;不详)
出处
《中国药物与临床》
CAS
2021年第8期1284-1289,共6页
Chinese Remedies & Clinics
